Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 31;13(8):1336-1340.
doi: 10.21037/tau-24-172. Epub 2024 Aug 12.

Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data

Goshi Kitano  1 , Takahiro Kojima  1
Affiliations
Editorial

Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data

Goshi Kitano et al. Transl Androl Urol. .
No abstract available

Keywords: IO-TKI combinations; Immuno-oncology (IO); KEYNOTE-426; tyrosine kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-24-172/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
HR for OS and PFS for each clinical trial over time. HR, hazard ratio; M, months of median follow-up; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

Comment on

References

    1. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1103-15. 10.1056/NEJMoa1816047 - DOI - PMC - PubMed
    1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed
    1. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019;380:1116-27. 10.1056/NEJMoa1816714 - DOI - PubMed
    1. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021;384:829-41. 10.1056/NEJMoa2026982 - DOI - PMC - PubMed
    1. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 2021;384:1289-300. 10.1056/NEJMoa2035716 - DOI - PubMed

LinkOut - more resources